MedEthix leverages synergy to ease molnupiravir access

FILIPINO pharmaceutical company MedEthix went beyond its way as the first importer to secure from the Food and Drug Administration the compassionate special permit (CSP) for molnupiravir — an oral drug indicated for mild to moderate cases of Covid-19 infection, which then enabled the standard of care to go beyond the confines of the over-stretched hospital wards and into the comforts of the patient’s home.

MedEthix further expanded the distribution of molnupiravir from the first four CSP grantees to over 80 health institutions and over 500 doctors as it successfully secured the emergency use authorization from the regulatory authority. The expanded access to affordable alternative treatment for Covid-19 benefited the Filipinos during the pandemic.

The advent of Covid-19, coming as it did exactly 100 years after the Spanish Influenza outbreak, caught the world by surprise. As a supply chain value enabler, MedEthix viewed Covid-19 as something that presented an opportunity to leverage its partnerships and optimize its internal resources and network, thus addressing the health care needs of the Filipinos.

The company’s capability to provide an end-to-end pharma supply chain solution has been recognized by the Healthcare Asia Pharma Awards as it takes home the Hospital Partnership of the Year – Philippines and the Most Differentiated Service of the Year – Philippines for this venture.

The prestigious awards program honored outstanding pharma companies in Asia that have demonstrated unwavering commitment to innovation and excellence and have redefined pharmaceutical excellence.